前立腺癌患者における好中球・リンパ球比の臨床的意義の検討

Abstract

Neutrophil-to-lymphocyte ratio (NLR), a simple marker of systemic inflammatory response, has clinical and prognostic value in patients with cancer. We evaluated the role of NLR prior to biopsy in patients suspected of having cancer prostate cancer. In this retrospective study, we reviewed the records of 204 patients who underwent prostate biopsy in Mizushima Kyodo Hospital between August 2002 and June 2015 and collected the following data : age, C-reactive protein (CRP), prostate volume (PV), clinical cancer staging, prostate-specific antigen (PSA) prior to biopsy , Gleason score (GS), NLR. NLR was calculated by prebiopsy neutrophil and lymphocyte counts. We divided the 83 of 204 patients found to have prostate cancer (PCa) into two or three groups by the results of biopsy, PSA, clinical cancer staging, GS, and D’Amico risk classification. Mann-Whitney U-test and Kruskal-Wallis H-test were used to compare NLR in each group. Significant differences were recognized in NLR between the groups : PSA≧10 ng/ml VS ＜ 10 ng/ml in all patients and in patients with cancer, cT2b≧ VS cT2c≦, GS 6 VS GS 7 VS GS 8≦ in patients with cancer and low risk VS intermediate risk VS high risk in patients with cancer without metastasis. Also we investigated the correlated factor with NLR in patients with cancer without metastasis. On multiple regression analysis including age, CRP, PV, PSA, clinical tumor stage and GS, PSA and GS had a significant association with NLR.